Changjiang Pharmaceutical Group (SHE:300391) said its subsidiary, Hubei Changjiang Xing Pharmaceutical, filed for bankruptcy reorganization by creditor Wuhan Century Baima System Engineering due to overdue debt of 6.2 million yuan, according to a Thursday filing with the Shenzhen Bourse.
The Shiyan Intermediate People's Court accepted the case on Feb. 11. The company is also undergoing pre-restructuring. Changjiang Xing plays a key role in the company's operations, and a successful restructuring could help resolve financial difficulties.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。